- Home
- LOCO vs LRMR Comparison
LOCO vs LRMR Comparison
Compare LOCO & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LOCO | LRMR |
|---|---|---|
| Founded | 1980 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 456.5M | 455.8M |
| IPO Year | 2014 | 2014 |
Fundamental Metrics
Financial Performance| Metric | LOCO | LRMR |
|---|---|---|
| Price | $14.30 | $3.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 6 |
| Target Price | $14.17 | ★ $16.50 |
| AVG Volume (30 Days) | 189.1K | ★ 913.0K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.65 | N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $401,701,000.00 | N/A |
| Revenue This Year | $3.60 | N/A |
| Revenue Next Year | $3.98 | $1,816.14 |
| P/E Ratio | $20.46 | ★ N/A |
| Revenue Growth | ★ 5.68 | N/A |
| 52 Week Low | $8.99 | $2.72 |
| 52 Week High | $17.40 | $6.42 |
Technical Indicators
Market Signals| Indicator | LOCO | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 34.39 | 44.98 |
| Support Level | $13.52 | $3.49 |
| Resistance Level | $14.38 | $4.20 |
| Average True Range (ATR) | 0.37 | 0.21 |
| MACD | -0.08 | -0.02 |
| Stochastic Oscillator | 2.51 | 22.34 |
Price Performance
Historical ComparisonAbout LOCO El Pollo Loco Holdings Inc.
El Pollo Loco Holdings Inc operates and franchises hundreds of fast-casual chicken restaurants in the United States. It specializes in fire-grilling citrus-marinated chicken and operates in the limited service restaurant market segment. Its offerings include Mexican-inspired menu items, including burritos, tostadas, bowls, salads, and bone-in chicken meals in various portion sizes. It also offers citrus-marinated fire-grilled chicken, along with a range of salsas and dressings that allow customers to customize their meals. The company operates in one operating segment. The majority of the company's revenue is derived from company-operated restaurant revenue.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.